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Hereditary pancreatitis is an autosomal dominant disease with variable expression
caused by mutations in the PRSS1 gene. Two other genes, SPINK1 and CFTR
are risk factors for pancreatitis and can be inherited in an autosomal recessive or
multifactorial fashion. Gene sequencing of all three genes aids in the diagnosis of
hereditary pancreatitis which can be difﬁcult to distinguish from a mild cystic ﬁbro-
sis phenotype. Manageability of data derived from the patient’s clinical presentation
and sequencing results is vital to understand genotype/phenotype correlation, to help
classify variants and to assure quality in laboratory reporting. To this end, we have
employed the clinical data management software, Progeny, to track genotypic and
phenotypic information on individuals and pedigrees. The database was customized
for pancreatitis patients. Data entered included patient demographics and clinical
presentation, laboratory sequencing results (nucleotide and amino acid changes for
CFTR, PRSS1 and SPINK1; mutation type and effect; and signiﬁcance of the variant)
and evidence for re-classiﬁcation of variants. Analysis of 59 pancreatitis cases
(classiﬁed as idiopathic, acute or chronic) found 10.2% of the patients carried one
CFTR mutation, 6.8% carried one CFTR and one SPINK1 mutation, 5.1% carried
one SPINK1 mutation, 5.1% carried one PRSS1 mutation and 1.7% carried two
CFTR mutations. No mutations were found in 71.2% of the cases. Progeny software
allows customized databases for combining clinical and laboratory information,
providing a means for accessible collection and querying of data.
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Cystic Fibrosis has 5% carrier rate in the Greek population and one of the highest rates of mutation
heterogeneity.
In this study we report 31 novel variants in the CFTR gene identiﬁed by DGGE analysis and
direct sequencing. Of these 2 were frameshift mutations leading to premature termination codon,
20 missense, 5 synonymous variants and 4 intronic substitutions. The effects of these mutations
were assessed in combination with the clinical phenotype and using in silico analysis. The missense
mutations were assessed using “PolyPhen”, “SIFT” and “Pmut”. The impact of the silent mutations
and the intronic substitutions on splicing elements was analysed using “SSF : Splicing Sequences
Finder”. Majority of ﬁndings included changes in splicing factor binding (not all data presented in
the Table).
These new ﬁndings pose difﬁculty in counselling, especially when they involve couples where one
member carries an established mutation and the other a novel variant. The only way to verify the true
effect of these variants is to perform functional studies (of the missense mutations) and RNA studies
(of synonymous variants and intronic substitutions) to conﬁrm the effect on splicing.
Exon Mutation Phenotype Polyphen
result
SIFT result Pmut result
4 c.538insACfs153X Classic CF N/A N/A N/A
20 c.3946delTGfs1300X Classic CF N/A N/A N/A
11 p.L541P Azoospermia Probably
damaging
Not tolerated (0.00) Pathological (6)
15 p.P936T Atypical CF Probably
damaging
tolerated (0.38) Pathological (4)
10 p.S945Y General population
screening
Probably
damaging
Not tolerated (0.00) Pathological (2)
1 p.M1R Asthma Probably
damaging
Not tolerated (0.00) Pathological (7)
11 p.M595V General population
screening
Probably
damaging
Not tolerated (0.02) Neutral (2)
19 p.K1165T Bronchitis Possibly
damaging
Not tolerated (0.04) Pathological (6)
15 p.S977C General population
screening
Possibly
damaging
Not tolerated (0.01) Pathological (5)
44 An adherence study using data from an AAD device in cystic
ﬁbrosis comparing early and late diagnoses
M.J. Archer1, V. Williams2, R.J. Rayner2. 1Royal Wolverhampton Hospitals NHS
Trust, Therapy Services, Wolverhampton, United Kingdom; 2Royal Wolverhampton
Hospitals NHS Trust, Paediatrics, Wolverhampton, United Kingdom
Background: In our District General Hospital (DGH) the CF multidisciplinary
team made a generalised observation that a group of patients diagnosed with CF late
(5−9 yrs old) had very poor adherence. We decided to do a small study to objectively
identify if this was the case and what other signiﬁcant barriers to adherence exist.
Objectives: To systematically identify the barriers to treatment adherence for
children with CF in a DGH. To examine any relationship between these barriers,
primarily whether or not a late or early diagnosis has any effect on adherence with
CF.
Methods: A quantitative design with adherence data was electronically monitored
via an AAD device. We used the Overall usage of the device as a percentage (over
the same 3 month period) for administering Promixin. 8/17 children with CF were
selected in accordance with the inclusion criteria, and put into 2 groups; 4 with
early diagnosis (<1 year) 4 with late diagnosis (>5 years). Age now 9−18 years.
Results: The early diagnosis group had improved adherence (Mean 61.33% SD),
than the later diagnosed group (Mean 27%) with the AAD device. This was highly
signiﬁcant (p 0.016), according to the t-test. Adherence was not associated with
any other variables apart from age at diagnosis.
Conclusion: Overall, adherence with an AAD device was signiﬁcantly improved
for those children who were diagnosed within the ﬁrst year of life than those with
a later diagnosis. Barriers to adherence need to be identiﬁed to enable the CF team
and families to act upon them and avoid important health consequences. Can we
assume that this poor adherence extends to other important aspects of their CF
care? Physiotherapy for example?
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Introduction: The SCC remains the gold standard for the diagnosis of Cystic
Fibrosis (CF). In newborn babies the amount of sweat collected to measure chloride
concentration may not be enough and delay the diagnosis. We designed a new
analyzer device for direct measurement of SCC (ISEsweat).
Aims: To assess both the performance and safety of the ISEsweat was compared
with the gold standard quantitative pilocarpine iontophoresis test (Q.P.I.T.).
Methods: The ISEsweat uses disposable sensors for the direct quantitative determi-
nation of SCC. Three CF Units participated. At each one, trained staff performed
both methods simultaneously. For the statistical analysis, the Bland–Altman and the
intraclass correlation coefﬁcient (ICC) were used to compare two methods.
Results: 42 individuals aged between 7 and 57 years participated in the study.
18 with CF and 24 healthy volunteers as controls. In CF patients SCC with
the ISEsweat device was 106.8±13.81mmol/L compared to 111.7±17.58mmol/L
with the standard SCC.In healthy volunteers with the ISEsweat device was
19.2±9.48mmol/L compared to 26.4±11.79mmol/L with the standard SCC. There
as a good correlation, between both methods using ICC= 0.95 was found (a = 0.05)
No adverse effects detected during this clinical assay.
Conclusions: We concluded that ISEsweat is a valid and safety new device for SCC
measurement. These preliminary results are very encouraging and warrant further
research with larger samples of patients, to conﬁrm that the ISEsweat can become a
useful tool for the diagnosis of CF and even prove to be a reliable more convenient
alternative method to the reference sweat test as approved by current guidelines.
